In re Jiangbo Pharmaceuticals, Inc.

520 B.R. 316, 2014 WL 6844698
CourtUnited States Bankruptcy Court, S.D. Florida.
DecidedNovember 24, 2014
DocketCase No. 13-15624-BKC-RBR
StatusPublished
Cited by2 cases

This text of 520 B.R. 316 (In re Jiangbo Pharmaceuticals, Inc.) is published on Counsel Stack Legal Research, covering United States Bankruptcy Court, S.D. Florida. primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In re Jiangbo Pharmaceuticals, Inc., 520 B.R. 316, 2014 WL 6844698 (Fla. 2014).

Opinion

Chapter 7

ORDER GRANTING MOTION, AS AMENDED, OF CHAPTER 7 TRUSTEE: TO APPROVE SETTLEMENT AND COMPROMISE OF CONTROVERSY WITH ELSA SUNG AND REQUEST FOR ENTRY OF A BAR ORDER [D.E. 101, 135] AND DENYING THE MOTION FOR RELIEF FROM STAY [D.E. 87]

Raymond B. Ray, Judge, United States Bankruptcy Court

THIS MATTER came before the Court for evidentiary hearing on September 19, 2014, upon the Motion of Chapter 7 Trustee Sonya L. Salkin (the “Trustee”): (I) to Approve Settlement and Compromise of Controversy with Former Officer of Debt- or, Elsa Sung (“Sung”), and Request for Entry of Bar Order; and (II) Requesting Authorization to Approve and Pay Earned Contingency Fee of $208,250 to the Trustee’s Special Counsel [D.E. 101] (the “9019 Motion”) and the Amendment to the 9019 Motion [D.E. 135]; the Securities Plaintiffs’ Limited Objection to the 9019 Motion [D.E. 114]; the Trustee’s Notice of Reliance Upon Supplemental Authority in Further Support of Approval of Settlement and Entry of Bar Order and Memorandum of Law [D.E. 138]; the Trustee’s Reply to Securities Plaintiffs’ Limited Objection [D.E. 139]; the Securities Plaintiffs’ Motion for Relief from the Automatic Stay [D.E. 87] (the “Stay Relief Motion”); the Trustee’s Response to the Stay Relief Motion [D.E. 116]; and the Rosen Law Firm, P.A.’s Response to the 9019 Motion and Cross Motion for Award of Attorneys’ Fee and Costs in the Amount of $210,808.69 and Fee Application [D.E. 117] (the “Ro-sen Pleading”); the Trustee’s Reply to the Rosen Pleading [D.E. 122].

After having considered the filings of the respective parties, all of the evidence presented and admitted, including the testimony and sworn declarations of the Trustee [D.E. 112, 137] and Peter Critchell (“Critchell”), a representative of the insurance carrier, National Union Fire Insurance Company of Pittsburgh, Pa. (“National Union”) [D.E. 136], taken judicial notice of documents pursuant to Federal Rule of Evidence 201 [D.E. 118], heard argument of counsel, and being otherwise duly advised in the premises, the Court finds and concludes as follows:

I. FINDINGS OF FACT

A. Background

On March 13, 2013 (the “Petition Date”), Pope Investments, LLC, Hua-Mei 21st Century Partners, LP, and Guerilla Partners, LP (collectively, the “Petitioning [319]*319Creditors”) filed a Chapter 7 Involuntary Petition against Jiangbo Pharmaceuticals, Inc. f/k/a Genesis Pharmaceuticals Enterprises, Inc. (“Jiangbo” or the “Debtor”) [D.E. 1], On April 15, 2013, the Court entered its Order for Relief in Involuntary Case and Order Setting Deadline for Filing Schedules, Statements, and Other Documents. [D.E. 17]. On April 17, 2013, Salkin- was appointed as the Chapter 7 Trustee in this case [D.E. 18] and she has-been administering the Estate since that date.

Prior to the Petition Date, certain shareholders of Jiangbo commenced a shareholder derivative action styled William Lindquist and Derek J. Bruce, Derivatively and on Behalf of Jiangbo Pharmaceuticals, Inc., v. Cao Wubo, et al., Case No. 11-23876-CIV-COOKE, pending in the United States District Court for the Southern District of Florida (the “Shareholder Derivative Action”). In their Second Amended and Consolidated Verified Shareholder Derivative Complaint (the “Complaint”), the plaintiffs sought an award of compensatory damages based on alleged acts and omissions of the Debtor’s former officers and directors (the “D & Os”). [Trustee Ex. 5]. Specifically, the Complaint alleges claims of Jiangbo against the D & Os for: (i) breach of fiduciary duty; (ii) corporate waste; (iii) gross mismanagement; and (iv) aiding and abetting breach of fiduciary duty (against Sung only) (collectively, the “D & 0 Claims”). [Trustee Ex. 5],

On May 22, 2013, the Trustee filed a Suggestion of Bankruptcy in the Shareholder Derivative Action advising the District Court and the parties of the pendency of the bankruptcy case and the imposition of the automatic stay pursuant to section 362. [Shareholder Derivative Action; D.E. 68]. On July 9, 2013, the Trustee filed a Notice of Removal removing the Shareholder Derivative- Action to this Court and instituting adversary proceeding 13-01503-RBR (the “D & O Adversary”). [Trustee Ex. 3]. On July 25, 2013, the Trustee filed a Motion to: (i) Intervene as Plaintiff in the Shareholder Derivative Action; (ii) Abate Case to Complete Ongoing Investigation; and (iii) Enforce the Automatic Stay with Respect to All Defendants [¶] & O Adversary; D.E. 12], which the Court granted on August 20, 2013 [¶] & O Adversary; D.E. 21],

Prior to the Petition Date, certain shareholders of Jiangbo (the “Securities Plaintiffs”) had commenced a class action lawsuit styled In re Jiangbo Pharmaceuticals, Inc. Securities Litigation, Case No. 11-22556-CIV-COOKE, pending in the United States District Court for the Southern District of Florida (the “Securities Class Action”), which alleged violations of U.S. securities laws. [Trustee Exs. 6, 7, 9]. Following a dismissal on the merits in favor of Sung [Trustee Exs. 8 & 10], the Securities Class Action is currently on appeal before the Eleventh Circuit Court of Appeals, Case No. 14-10213-DD. [Trustee Exs. 12, 13, 14], On September 25, 2013, the Securities Plaintiffs filed Proof of Claim No. 5 against the Estate and attached a copy of their Second Amended Complaint for Violations of Securities Laws. [Trustee Exs. 1, 2, 9].

Prior to the Petition Date, National Union issued an Executive and Organization Liability Policy, Policy No. 01-421-72-35 (the “D & O Policy”), covering certain claims made and reported against Jiangbo and its D & Os during the one-year Policy Period beginning December 14, 2009. [Trustee Ex. 15]. The D & O Policy is a $3,000,000 “wasting policy”. Critchell of National Union testified that: (i) National Union was and had been advancing defense costs for Sung’s defense as to the claims asserted against Sung in the Share[320]*320holder Derivative Action, the D & 0 Adversary, and the Securities Class Action; (ii) as of September 10, 2014, National Union advanced $1,262,126 in defense fees and costs for Sung under the D & 0 Policy; (iii) continued litigation will cause this number to substantially increase over time; and (iv) National Union may need to reserve certain D & 0 Policy funds in connection with the defense of any investigation and enforcement action by governmental entities.

On January SI, 2014, the Court entered an Agreed Order Granting the Securities Plaintiffs Relief from the Automatic Stay, and required that the Trustee, Sung, and the Securities Plaintiffs attend and participate in a joint mediation conference “in a good faith attempt to reach a global resolution.” [DE. 96] (the “Agreed Order”). On February 24, 2014, the Trustee, Sung, and National Union (the “Settling Parties”) and the Securities Plaintiffs mediated their respective claims, demands, and defenses involving Jiangbo. The Trustee testified at the evidentiary hearing that before and after the mediation and the preliminary hearings on the 9019 Motion she made attempts to include the Securities Plaintiffs in a global settlement, to no avail.

B. The Settlement and the 9019 Motion as Amended

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Securities and Exchange Commission v. Ariel Quiros
966 F.3d 1195 (Eleventh Circuit, 2020)
United States v. Hartog
597 B.R. 673 (S.D. Florida, 2019)

Cite This Page — Counsel Stack

Bluebook (online)
520 B.R. 316, 2014 WL 6844698, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-jiangbo-pharmaceuticals-inc-flsb-2014.